
News|Articles|August 14, 2025
Early Experience of Aflibercept 8mg (EYLEA® 8mg) in Routine Clinical Practice
Advertisement
Sponsored Supplement:
One-to-one interviews with three leading retina specialists from Switzerland, United Kingdom and United States on their early experience of aflibercept 8mg (EYLEA® 8mg) in clinical practice, capturing contemporary insights on treatment strategies and real-world outcomes in patients with neovascular age-related macular degeneration and diabetic macular edema.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
DEX implant shows benefit across RVO subgroups in real-world retrospective study
2
Demodex blepharitis: Closing the diagnostic gap to improve ocular surface health
3
European Dry Eye Society Congress 2026: real-world evidence on Artelac Complete in dry eye disease
4
AI-predicted retinal function shows promise in geographic atrophy
5

























